Company Insights

LIXT supplier relationships

Explore interactive graphBrowse insights index
LIXT supplier relationship map

LIXT supplier map: who Lixte hires, collaborates with, and why it matters to investors

Lixte Biotechnology Holdings (NASDAQ: LIXT) operates as a small-cap clinical-stage biotech that monetizes through clinical collaborations, licensing of core intellectual property, selective acquisitions, and periodic capital raises. The company advances its proprietary oncology compound LB-100 by partnering with large pharma for drug supply and trial support, contracting clinical operations and vendor services, and tapping capital markets via placement agents and counsel for registered offerings. For investors evaluating counterparty risk or operational leverage, the supplier network reveals a mixed contracting posture—long-term IP licensing and trial support combined with short-term vendor engagements and concentrated R&D spend. Learn more or run a supplier risk scan at https://nullexposure.com/.

How LIXT sources capital and legal support

  • Spartan Capital Securities, LLC. Served as exclusive placement agent for Lixte’s $4.3 million registered direct offering, a clear indicator the company uses boutique investment banks to access dilutive capital efficiently. (Source: GlobeNewswire press release, Dec 18, 2025; also reported via Yahoo Finance, FY2025–FY2026.)

  • Sichenzia Ross Ference Carmel LLP. Acted as legal counsel for Lixte’s registered offering, providing corporate securities and transaction support for the financing. (Source: GlobeNewswire press release, Dec 18, 2025; Yahoo Finance coverage, FY2025–FY2026.)

These two relationships show Lixte’s standard capital-formation playbook: small, targeted raises executed through a placement agent with specialized securities counsel rather than broad investment bank syndicates.

Pharma partners supplying drugs and funding for pivotal trials

  • GSK plc (GSK). GSK supplies dostarlimab for combination trials and provides financial support for clinical trials evaluating LB-100 in ovarian and other indications; Lixte expanded collaborations with MD Anderson and Northwestern using GSK’s drug supply. (Source: Lixte press releases and news coverage, including GlobeNewswire and NewMediaWire, FY2025–FY2026; FY2024 company disclosures also reference the arrangement.)

  • F. Hoffmann‑La Roche / Roche. Roche is supplying atezolizumab and contributing financial support for a colorectal cancer trial being conducted at the Netherlands Cancer Institute. (Source: Lixte FY2024 10‑K and GlobeNewswire corporate update, Aug 18, 2025.)

These supplier relationships are critical to trial execution because large pharma provides both the comparator/partner agents and cash support that reduce the company’s out‑of‑pocket trial burden and improve regulatory and scientific credibility.

Acquisitions and operational subsidiaries that change the supplier landscape

  • Orbit Capital, Inc. Played an intermediary role in the creation of Liora and facilitated the sale of Liora’s assets to Lixte in November 2025; Orbit’s involvement reflects how Lixte sources growth through targeted asset transactions. (Source: Globenewswire press release announcing the Liora asset acquisition and executive appointments, Feb 18, 2026, FY2026.)

  • Liora (LiGHT System). Lixte acquired Liora’s assets and appointed Sidney Braun to lead Liora Technologies Europe Ltd., signaling a strategic move into an electronically controlled proton therapy platform that complements LB-100’s oncology focus. (Source: Globenewswire and NewMediaWire, Feb 2026; FY2026.)

The Liora acquisition shows Lixte’s tactical expansion into therapeutic device assets, shifting some supplier risk from external vendors to owned operations and a nascent subsidiary structure.

Investor relations and communications suppliers

  • PondelWilkinson Inc. Listed repeatedly as the company’s investor relations contact across press releases, indicating Lixte uses external IR firms to manage market communications and investor outreach. (Source: GlobeNewswire releases, Sep 10, 2025 and Jan 20, 2026, FY2025–FY2026.)

  • Investor Brand Network (IBN) / InvestorBrandNetwork. Used as a distribution channel for corporate news and promotional releases, reflecting Lixte’s use of paid newswires and investor outreach services. (Source: multiple press distributions in The Globe and Mail, DigitalJournal and markets outlets, FY2026.)

External IR and news distribution partners highlight how market visibility and retail investor engagement are outsourced, which matters for liquidity and information flow but carries reputational and messaging dependency.

Full list of relationships pulled from public notices (concise takeaways)

  • Spartan Capital Securities, LLC — Exclusive placement agent for a $4.3M registered direct offering; shows reliance on capital markets intermediaries. (GlobeNewswire/Yahoo Finance, FY2025–FY2026.)
  • Sichenzia Ross Ference Carmel LLP — Securities counsel for the registered direct offering. (GlobeNewswire/Yahoo Finance, FY2025–FY2026.)
  • GSK plc — Supplies dostarlimab and funds clinical trials, partnering on LB-100 combination studies at leading cancer centers. (Lixte press releases and FY2024 filing; GlobeNewswire and NewMediaWire, FY2025–FY2026.)
  • F. Hoffmann‑La Roche / Roche — Provides atezolizumab and trial funding for colorectal work at the Netherlands Cancer Institute. (Lixte FY2024 10‑K; GlobeNewswire, FY2025.)
  • Orbit Capital, Inc. — Facilitator of the Liora asset transaction that Lixte closed in Nov 2025. (GlobeNewswire press release, Feb 18, 2026, FY2026.)
  • Liora — Acquired asset line (LiGHT System); new subsidiary leadership points to operational integration goals. (GlobeNewswire/NewMediaWire, FY2026.)
  • PondelWilkinson Inc. — Investor relations vendor and media contact across multiple press releases. (GlobeNewswire press releases, FY2025–FY2026.)
  • Investor Brand Network / IBN — Newsroom/distribution channel used for corporate communications and investor outreach. (DigitalJournal, The Globe and Mail, markets outlets, FY2026.)

What LIXT’s supplier constraints reveal about its operating model

The company’s filings and work orders show a hybrid contracting posture: an exclusive long‑term licensing stance for core IP combined with short‑term vendor engagements for operations.

  • Long‑term, strategic IP licensing: Lixte executed a Patent License Agreement with NIH centers (NINDS/NCI) granting exclusive rights, structured to last until the last‑to‑expire patent claim—effectively a multi‑decade IP backbone for commercialization (company 10‑K, FY2024).
  • Project-level clinical service contracts: Work orders such as the Theradex monitoring agreement extend into 2026–2027 and are task-focused, time‑bound contracts supporting trial oversight. (Company filing excerpts on clinical work orders.)
  • Short‑term consulting and vendor engagements: Routine one‑year or per‑project contracts handle trial logistics, IR, and communications. The firm’s R&D cost profile shows concentration: three vendors accounted for ~83.6% of R&D costs in FY2024, making individual supplier performance materially relevant. (Company 10‑K, FY2024.)
  • Geographic footprint: R&D spend is concentrated in the United States, with meaningful EMEA activity (Netherlands, Spain) and limited APAC exposure (China), pointing to trial and regulatory focus across US and European hubs. (Company FY2024 disclosures.)
  • Spend scale: Vendor spend signals align with the $100k–$1m band, consistent with small‑scale CRO, IR, and trial services for a company at this stage.

Investment implications and operator playbook

  • Positive: Pharmaceutical supplier support from GSK and Roche is a structural advantage—it lowers cash burn and raises scientific credibility. The Liora acquisition diversifies assets into radiation therapy tools, offering optionality beyond a single drug program.
  • Risks: Vendor concentration and reliance on small capital raises create execution and liquidity sensitivity; a failed milestone or vendor disruption would have outsized effects on operating timelines and cash management. The company’s mixed use of short-term vendors and long-term IP licensing means operational fragility is paired with long-term IP upside.

For a deeper counterparty risk profile and to track supplier concentration over time, run a targeted supplier exposure review at https://nullexposure.com/. If you manage biotech exposure or evaluate CRO/legal vendor risk, the supplier map on the platform provides structured signals tailored to investors and operators: https://nullexposure.com/.

Bottom line: Lixte’s supplier ecosystem is deliberately small and concentrated, anchored by big‑pharma clinical support and augmented by targeted capital market and IR partners—a structure that supports near-term trials but exposes the company to concentrated vendor and financing risk. For portfolio-level decisions, prioritize monitoring of trial milestones, vendor performance, and subsequent capital raises.